Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4622957 | 1.00 | MMP2 (0.64) | MMP2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL463120 | 1.00 | MMP2 (0.64) | MMP2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL6562730 | 0.88 | MMP2 (0.60) | MMP2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL6522414 | 0.85 | MMP2 (0.61) | MMP2LMNADPP4DPP7 | |
| SCHEMBL6798022 | 0.83 | MMP2 (0.56) | MMP2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL7065249 | 0.83 | MMP2 (0.56) | MMP2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL7065251 | 0.83 | MMP2 (0.56) | MMP2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL6100385 | 0.82 | MMP2 (0.59) | MMP2LMNAKMT2ADPP4DPP7 | |
| SCHEMBL5000615 | 0.82 | MMP2 (0.59) | MMP2LMNAKMT2ADPP4DPP7 | |
| Hydrochloric Acid SCHEMBL6803379 | 0.82 | MMP2 (0.55) | MMP2LMNAMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1157004-A1 | REGIOSELECTIVE SYNTHESIS OF DTPA DERIVATIVES | IDEC PHARMACEUTICALS CORPORATION (US) | 2001-11-28 | — | — | EP | claimed |
| US-6207858-B1 | ELIMINATES THE NEED FOR ION EXCHANGE CHROMOTOGRAPHIC SEPARATION OF INTERMEDIATES, USEFUL AS BI-FUNCTIONAL CHELATORS IN RADIOIMMUNOTHERAPY AND IMAGING, DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA), SUITABLE FOR | IDEC PHARMACEUTICALS CORPORATION | 2001-03-27 | — | — | US | claimed |
| WO-2000051976-A1 | REGIOSELECTIVE SYNTHESIS OF DTPA DERIVATIVES | IDEC PHARMACEUTICALS CORPORATION (US) | 2000-09-08 | — | — | WO | claimed |
| EP-1157004-B1 | Composition comprising MX-DTPA and its use to produce a radiolabeled MX-DTPA | BIOGEN IDEC INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7368100-B2 | Backbone-substituted bifunctional DOTA ligands, complexes and compositions thereof, and methods of using same | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-05-06 | — | — | US | disclosed |
| US-20060165600-A1 | Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same | GOVERNMENT OF THE U.S.A., REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SVCS. (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1157004-A1 | REGIOSELECTIVE SYNTHESIS OF DTPA DERIVATIVES | IDEC PHARMACEUTICALS CORPORATION (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6207858-B1 | ELIMINATES THE NEED FOR ION EXCHANGE CHROMOTOGRAPHIC SEPARATION OF INTERMEDIATES, USEFUL AS BI-FUNCTIONAL CHELATORS IN RADIOIMMUNOTHERAPY AND IMAGING, DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA), SUITABLE FOR | IDEC PHARMACEUTICALS CORPORATION | 2001-03-27 | — | — | US | disclosed |
| WO-2000051976-A1 | REGIOSELECTIVE SYNTHESIS OF DTPA DERIVATIVES | IDEC PHARMACEUTICALS CORPORATION (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060165600-A1 | Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same | UACA, PAICS, TBCA | MMP2 4301/4885LMNA 870/4885MEN1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.